Aligos Therapeutics Inc (ALGS)

1.12 +0.02 (+1.82%) USD  |  NASDAQ  |  May 26, 16:00
1.10 -0.02 (-1.79%) After-Hours: 20:00
More

Aligos Therapeutics News

News

Headline
Wire
Time (ET)
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
Globe Newswire
05/24 17:26
Sector Update: Health Care Stocks Edge Higher Premarket Monday
MT Newswires
05/15 09:06
Top Premarket Gainers
MT Newswires
05/15 07:52
Aligos Therapeutics to Collaborate with Xiamen Amoytop Biotech on Liver Disease Treatments; Aligos Shares Jump
MT Newswires
05/15 07:45
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
Yahoo
05/12 17:05
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
Yahoo
05/04 19:25
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
Globe Newswire
05/04 16:05
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
Yahoo
04/27 16:05
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 30% Dip In Price Shows Sentiment Is Matching Revenues
Yahoo
04/17 06:51
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
Yahoo
04/11 18:50
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
Yahoo
03/29 16:05
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
Yahoo
03/09 18:25
Aligos Therapeutics GAAP EPS of -$0.51 misses by $0.02, revenue of $3.54M beats by $1.39M
SA Breaking News
03/09 16:46
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q4 Revenue $3.5M, vs. Street Est of $2.15M
MT Newswires
03/09 16:16
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
Globe Newswire
03/09 16:05
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
Yahoo
03/09 16:05
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
Yahoo
02/28 16:05
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
Globe Newswire
02/16 08:00
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
Globe Newswire
02/14 08:00
Aligos Therapeutics Announces Portfolio Reprioritization Plans, Workforce Reduction
MT Newswires
02/09 13:49
Aligos Therapeutics in portfolio reorganization focused on NASH, COVID assets
SA Breaking News
02/08 17:44
Piper Sandler Adjusts Price Target on Aligos Therapeutics to $7 From $3, Maintains Overweight Rating
MT Newswires
01/17 09:36
RIOT, MARA and CLSK are among pre market gainers
SA Breaking News
01/17 08:18
--Piper Sandler Upgrades Aligos Therapeutics to Overweight From Neutral, Adjusts Price Target to $3 From $2
MT Newswires
01/06 10:19
--Jefferies Upgrades Aligos Therapeutics to Buy From Hold, Adjusts Price Target to $3 From $2.50
MT Newswires
01/06 08:27
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
Globe Newswire
01/05 08:00
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
Globe Newswire
12/08 08:00
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
Globe Newswire
11/04 08:05
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
Globe Newswire
11/04 08:00
--SVB Securities Adjusts Aligos Therapeutics' Price Target to $2 From $3, Keeps Market Perform Rating
MT Newswires
11/03 13:13
Aligos Therapeutics GAAP EPS of -$0.44 beats by $0.14, revenue of $4.12M beats by $3.37M
SA Breaking News
11/02 16:51
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Reports Q3 Revenue $4.1M, vs. Street Est of $0.75M
MT Newswires
11/02 16:18
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q3 Loss $-0.44, vs. Street Est of $-0.58
MT Newswires
11/02 16:17
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
Globe Newswire
11/02 16:05
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
Globe Newswire
10/21 09:05
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Globe Newswire
10/18 07:30
Aligos Therapeutics Starts Dosing Healthy Participants in Hepatitis B Phase 1 Study of Drug Candidate ALG-125755
MT Newswires
10/14 09:04
Aligos Therapeutics files court response and counterclaims to J&J's allegations of theft
SA Breaking News
09/28 18:45
--Cantor Fitzgerald Downgrades Aligos Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.20 From $11
MT Newswires
08/08 08:52
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q2 Revenue $3.7M
MT Newswires
08/04 16:28
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Reports Q2 Loss $-0.47
MT Newswires
08/04 16:28
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
Globe Newswire
08/04 16:05
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
Globe Newswire
07/27 16:05
Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
SA Breaking News
07/25 10:08
Aligos Therapeutics Starts Patient Enrollment in Phase 1b Trial of Hepatitis B Drug Candidate
MT Newswires
07/25 08:55
Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184
Globe Newswire
07/25 08:00
Top Premarket Decliners
MT Newswires
07/08 07:49
Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress™ 2022
Globe Newswire
06/22 08:00
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
Globe Newswire
05/23 16:05
Top Premarket Gainers
MT Newswires
05/17 07:50
--SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to $3 From $7
MT Newswires
05/05 07:11
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q1 Loss $-0.84, vs. Street Est of $-0.77
MT Newswires
05/04 16:39
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
Globe Newswire
05/04 16:05
Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International Liver Congress™ 2022
Globe Newswire
05/03 08:00
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
Globe Newswire
04/27 16:05
Aligos Therapeutics Picks COVID-19 Drug Candidate to Advance into Development
MT Newswires
04/04 10:33
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development
Globe Newswire
04/04 08:00
--Jefferies Lowers Price Target for Aligos Therapeutics to $2.50 From $5, Maintains Hold Rating
MT Newswires
03/23 08:54
--SVB Leerink Adjusts Aligos Therapeutics' Price Target to $7 from $11, Keeps Outperform Rating
MT Newswires
03/23 08:53
Piper Sandler Cuts Aligos Therapeutics to Neutral From Overweight, Price Target to $4 From $15
MT Newswires
03/23 05:13
Aligos Therapeutics Discontinues Development of Potential Chronic Hepatitis B Treatment; Shares Down Pre-Bell
MT Newswires
03/22 09:00
Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
Globe Newswire
03/22 08:00
--SVB Leerink Adjusts Aligos Therapeutics' Price Target to $11 from $10, Keeps Outperform Rating
MT Newswires
03/11 11:25
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q4 Revenue $367,000
MT Newswires
03/10 16:07
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Reports Q4 Loss $-0.89, vs. Street Est of $-0.83
MT Newswires
03/10 16:07
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Globe Newswire
03/10 16:05
Bragar Eagel & Squire, P.C. Is Investigating Everbridge, Aligos, Clariant, and Natera and Encourages Investors to Contact the Firm
Globe Newswire
02/21 21:00
Bragar Eagel & Squire, P.C. Is Investigating Everbridge, Aligos, SunPower, and Natera and Encourages Investors to Contact the Firm
Globe Newswire
02/16 21:00
--SVB Leerink Adjusts Aligos Therapeutics' Price Target to $10 from $15, Maintains Outperform Rating
MT Newswires
02/16 12:52
Top Premarket Gainers
MT Newswires
02/14 08:02
Bragar Eagel & Squire, P.C. Is Investigating Everbridge, Aligos, Labcorp., and SunPower and Encourages Investors to Contact the Firm
Globe Newswire
02/11 21:00
Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Globe Newswire
02/03 16:05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS
Globe Newswire
02/01 18:29
Bragar Eagel & Squire, P.C. Is Investigating Everbridge, Hollysys, Aligos, and Labcorp. and Encourages Investors to Contact the Firm
Globe Newswire
01/31 21:00
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS
PR Newswire
01/27 21:40
Bragar Eagel & Squire, P.C. Is Investigating Aligos, SunPower, and Labcorp and Encourages Investors to Contact the Firm
Globe Newswire
01/26 21:00
Sector Update: Health Care Stocks Catching Up With Late Market Declines
MT Newswires
01/26 16:01
Aligos Therapeutics Doses First Hepatitis B Patient in Phase 1 Trial of Antisense Therapy
MT Newswires
01/26 09:23
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
Globe Newswire
01/26 08:00
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS
Globe Newswire
01/23 13:35
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS
PR Newswire
01/17 20:23
(ALGS) News: Did You Lose Money on Your Aligos Therapeutics Stock? Contact Johnson Fistel Regarding Investigation
Globe Newswire
01/13 11:01
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS
Globe Newswire
01/13 10:01
Aligos expands collaboration with Merck to develop oligonucleotide therapies for NASH
SA Breaking News
01/11 10:53
Aligos Therapeutics, Merck Expand Collaboration in Nonalcoholic Steatohepatitis
MT Newswires
01/11 10:16
--Jefferies Downgrades Aligos Therapeutics to Hold From Buy, Adjusts Price Target to $5 From $20
MT Newswires
01/07 16:17
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS
PR Newswire
01/07 14:11
--SVB Leerink Adjusts Aligos Therapeutics' Price Target to $15 from $29, Keeps Outperform Rating
MT Newswires
01/07 13:30
--JPMorgan Lowers Aligos Therapeutics to Neutral From Overweight, Price Target to $12 From $30
MT Newswires
01/07 06:10
Top Midday Decliners
MT Newswires
01/06 14:25
BYND, VCRA, EMBK among mid-day movers
SA Breaking News
01/06 13:15
Aligos falls on decision to halt development of chronic hepatitis B candidate
SA Breaking News
01/06 10:34
Aligos Therapeutics Ceases Development of Chronic Hepatitis B Drug Candidate
MT Newswires
01/06 08:55
Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133
Globe Newswire
01/06 08:00
Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Globe Newswire
12/21 16:05
Aligos Therapeutics Begins Dosing in Study of ALG-055009 to Treat Nonalcoholic Steatohepatitis
MT Newswires
12/09 09:17
Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study
Globe Newswire
12/09 08:00
Warning: ALGS is at high risk of performing badly
SA Breaking News
12/09 04:27
Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021
Globe Newswire
12/07 08:00
Aligos Therapeutics Signs Drug Discovery Agreement With Vipergen Focused on Viral Infections, Liver Diseases
MT Newswires
11/23 09:13
Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases
PR Newswire
11/23 07:00
Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Globe Newswire
11/22 08:00
Aligos Therapeutics to Present Virtually at the Jefferies London Healthcare Conference 2021
Globe Newswire
11/15 16:05
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q3 Revenue $1.5M
MT Newswires
11/04 16:35
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q3 Loss $-0.78, vs. Street Est of $-0.82
MT Newswires
11/04 16:35
Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021
Globe Newswire
10/28 16:05
Aligos Therapeutics Begins Dosing in Study of ALG-020572 to Treat Hepatitis B
MT Newswires
10/11 09:08
Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study
Globe Newswire
10/11 08:00
Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
Globe Newswire
09/20 16:05
--SVB Leerink Starts Aligos Therapeutics at Outperform with $29 Price Target
MT Newswires
09/09 11:58
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q2 Revenue $1.55M
MT Newswires
08/05 16:16
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q2 Loss $-0.79, vs. Street Est of $-0.81
MT Newswires
08/05 16:16
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
Globe Newswire
08/05 16:05
Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
Globe Newswire
07/29 16:05
MFGP, NVCR, SLCA and CTXR among midday movers
SA Breaking News
07/01 13:06
Aligos Therapeutics secures $83.6M capital via equity raise
SA Breaking News
06/30 23:45
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
Globe Newswire
06/30 22:08
Technology and Healthcare names dominate midday movers
SA Breaking News
06/29 12:34
Aligos Therapeutics Announces Proposed Public Offering of Common Stock
Globe Newswire
06/28 16:10
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
Globe Newswire
06/21 08:00
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
Globe Newswire
06/14 08:00
Aligos Reports 'Promising' Early Results From Hepatitis B Study, Shares Rise
MT Newswires
06/10 15:37
Aligos trades higher on early-stage data for Hep B candidate
SA Breaking News
06/10 15:35
Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference
Globe Newswire
06/10 07:00
Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Globe Newswire
05/20 16:05
--Piper Sandler Initiates Coverage on Aligos Therapeutics With Overweight Rating, $47 Price Target
MT Newswires
05/17 12:00
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results
Globe Newswire
05/10 16:05
Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021
Globe Newswire
05/05 08:00
Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors
Globe Newswire
04/27 16:01
Aligos announces dosing initiation of patients in chronic hepatitis B trial
SA Breaking News
04/14 08:53
Aligos Therapeutics Begins Dosing Patients in Study of ALG-000184 to Treat Chronic Hepatitis B
MT Newswires
04/14 08:32
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
Globe Newswire
04/14 08:00
Seeking Alpha Catalyst Watch
SA Breaking News
04/09 13:30
--Analyst Actions: Piper Sandler Adjusts Price Target on Aligos Therapeutics to $40 From $35, Maintains Overweight Rating
MT Newswires
03/24 10:58
Aligos Therapeutics Narrows Q4 Loss From Year Ago
MT Newswires
03/23 17:01
Aligos Therapeutics EPS misses by $0.19
SA Breaking News
03/23 16:57
-- Earnings Flash (ALGS) ALIGOS THERAPEUTICS Reports Q4 Loss $-1.09
MT Newswires
03/23 16:09
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Globe Newswire
03/23 16:05
Aligos Starts Patient Dosing in Phase 1 Trial of ALG-010133 in Chronic Hepatitis B Patients
MT Newswires
03/10 11:10
Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
Globe Newswire
03/10 08:00
Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections
Globe Newswire
03/08 08:00
DDD, NVAX, LMND and RKT among midday movers
SA Breaking News
03/02 13:08
Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver
Globe Newswire
02/03 08:00
Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Globe Newswire
01/07 08:00
--Analyst Actions: Jefferies & Co Adjusts Aligos Therapeutics PT to $30 From $26, Maintains Buy Rating
MT Newswires
12/21 12:30
Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020
Globe Newswire
12/17 08:00
Aligos Therapeutics Climbs Amid Oligonucleotide Therapy Collaboration With Merck
MT Newswires
12/07 10:17
Aligos enters into an agreement with Merck to discover and develop an oligonucleotide therapy for NASH
SA Breaking News
12/07 09:12
Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH
Globe Newswire
12/07 08:00
Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD’s The Liver Meeting Digital Experience™ 2020
Globe Newswire
11/16 08:00
Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
Globe Newswire
11/13 08:00
Aligos Therapeutics Secures $2.1 Million Grant To Advance Chronic Hepatitis B Research
MT Newswires
11/12 13:20
Aligos Therapeutics secures €1.8M grant to advance hepatitis B research
SA Breaking News
11/12 08:45
Aligos Therapeutics is awarded €1.8M VLAIO grant to advance chronic hepatitis B research
Globe Newswire
11/12 08:00
--Analyst Actions: Cantor Fitzgerald Starts Aligos Therapeutics at Overweight With $28 Price Target
MT Newswires
11/10 09:09
--Analyst Actions: Piper Sandler Starts Aligos Therapeutics at Overweight With $35 Price Target
MT Newswires
11/10 09:09
--Analyst Actions: JPMorgan Starts Aligos Therapeutics at Overweight With $33 Price Target
MT Newswires
11/10 09:09
--Analyst Actions: Jefferies & Co Initiates Coverage on Aligos Therapeutics With Buy Rating, $26 Price Target
MT Newswires
11/10 09:08
Aligos Therapeutics Starts Dosing in Early-Stage Human Trial of Investigational Chronic Hepatitis B Treatment
MT Newswires
10/30 11:10
Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study
SA Breaking News
10/30 08:32
Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B
Globe Newswire
10/30 08:00
FISV, TCOM, FLDM and SELB among after-hours movers
SA Breaking News
10/16 17:42
Aligos Therapeutics Prices IPO At $15 Per Share, Within Expected Range
MT Newswires
10/16 04:53
Aligos Therapeutics prices $150M IPO
SA Breaking News
10/15 23:02
Aligos Therapeutics Announces Pricing of Initial Public Offering
Globe Newswire
10/15 22:19